EP Patent

EP4116710A4 — USE OF A PANEL OF MARKERS FOR THE DIAGNOSIS AND ADJUSTMENT OF TREATMENT OF PRIMARY BILIAL CHOLANGITIS, PHARMACEUTICAL COMPOSITION AND SOLID DOSAGE FORM FOR THE TREATMENT OF PRIMARY BILIAL CHOLANGITIS

Assigned to Mili Healthcare Ltd · Expires 2024-04-24 · 2y expired

What this patent protects

Patent listed against Ocaliva.

Drugs covered by this patent

Patent Metadata

Patent number
EP4116710A4
Jurisdiction
EP
Classification
—
Expires
2024-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Mili Healthcare Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.